CREB1 and ovarian carcinoma: We found that Roflumilast could phosphorylate CREB to up-regulate the level of FtMt, and the promoter region of FtMt was reported to harbor the binding site of CREB [17], which implicated that the increased expression of FtMt in ovarian cancer was attributed to the transcription of CREB.